Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Antibiotics in Chronic Rhinosinusitis
NCT03673956Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2018
- Primary completion
- Feb 2021
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mupirocin, tobramycin, levofloxacin and vancomycin in chronic rhinosinusitis (CRS) (4 arms), sponsored by Mayo Clinic. Primary endpoint: Subjects Who Developed Antibiotic Resistance Organisms. Started Sep 2018; status: completed.
02
Drugs
mupirocintobramycinlevofloxacinvancomycin
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT03673956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673956.